Archives of Gynecology and Obstetrics

, Volume 274, Issue 5, pp 289–296 | Cite as

The effect of hormone replacement therapy on the levels of serum lipids, apolipoprotein AI, apolipoprotein B and lipoprotein (a) in Turkish postmenopausal women

Original Article

Abstract

Objectives

Estrogen replacement therapy alters the lipid profiles favorably for delaying atherosclerosis in postmenopausal women. The effects of estrogen plus progesterone combination therapy on lipids are controversial. This study was designed to evaluate the effect of female sex hormones on lipids and lipoproteins and to clarify the influence of progesterone on the effect of estrogen in postmenopausal women.

Methods

Of the 60 postmenopausal women admitted to our menopause clinic, 40 had intact uterus and received continuous 0.625 mg conjugated equine estrogen (CEE) plus 2.5 mg medroxyprogesterone acetate (MPA), whereas the remaining 20 were hysterectomized and received 0.625 mg CEE daily. To assess the alterations in lipids and lipoproteins during menopause, 45 healthy premenopausal women were investigated. Lipid and lipoprotein levels were assessed in each subject at baseline and at the 6th and 18th months of therapy.

Results

In menopause, a shift towards more atherogenic lipid and lipoprotein profiles than those of the premenopausal state was found. Following 18 months of treatment, both regimens reduced total cholesterol (TC) levels as compared with the baseline (6.4 vs. 6.9% in the CEE/MPA and CEE groups, respectively). The CEE group had a more pronounced increase in high-density lipoprotein (HDL) cholesterol than the CEE/MPA group (10.3 vs. 8.8%, respectively). Both groups displayed reduced TC, low-density lipoprotein (LDL) cholesterol and apolipoprotein-B (ApoB) concentrations, whereas triglycerides increased, with a greater tendency to increase in the CEE/MPA group at the end of the trial. Also, the lipoprotein (a) [Lp(a)] levels decreased significantly (27.6 vs. 24.5% in the CEE/MPA and CEE groups, respectively). This decrease was more pronounced in subjects with a relatively higher basal Lp(a) concentration.

Conclusion

Both treatment regimens caused positive alterations in the lipid and lipoprotein profiles. This association might play a pivotal role in the postmenopausal increases in atherosclerotic diseases and cardioprotective effect of estrogen in postmenopausal women.

Keywords

ERT HRT Lipids Lipoproteins Atherosclerotic diseases Coronary heart disease Cardioprotective effect of estrogen 

References

  1. 1.
    Nathan L, Chaudhuri G (1997) Estrogens and atherosclerosis. Annu Rev Pharmacol Toxicol l37:477–515CrossRefGoogle Scholar
  2. 2.
    Chang TC, Lien YR, Chen M, Cheng SP et al (2004) Effect of conjugated eguine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study. Acta Obstet Gynecol Scand 83:661–666PubMedCrossRefGoogle Scholar
  3. 3.
    Christodoulakos GE, Lambrinoudaki IV, Panoulis CP, Papadias CA, Kouskouni EE et al (2004) Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids and lipoprotein in Greek postmenopausal women. Gynecol Endocrinol 18:244–257PubMedCrossRefGoogle Scholar
  4. 4.
    Solomon CG, Dluhy (2003) Rethinking postmenopausal hormone therapy. N Engl J Med 348:579–580PubMedCrossRefGoogle Scholar
  5. 5.
    Writing Group for the Women’s Health Initiative (WHI) Investigators (2002) Risk and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288:321–333CrossRefGoogle Scholar
  6. 6.
    Grady D, Yaffe K, Kristof M, Lin F, Richards C, Barrett-Connor E (2002) Effect of postmenopausal hormone therapy on cognatitive function: The Heart and Estrogen/Progestin Replacement Study. Am J Med 113:543–548PubMedCrossRefGoogle Scholar
  7. 7.
    Ettinger B, Friedman GD, Bush T, Quesenberry CP (1996) Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 87:6–12PubMedCrossRefGoogle Scholar
  8. 8.
    Wiklund I, Karlberg J, Mattsson LA (1993) Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. Am J Obstet Gynecol 168:824–830PubMedGoogle Scholar
  9. 9.
    Grady D (2003) Postmenopausal hormones—therapy for symptoms only. N Engl J Med 348:1835–1837PubMedCrossRefGoogle Scholar
  10. 10.
    Grambrell RD Jr (1982) The menopause: benefits and risk of estrogen-progestogen replacement therapy. Fertil Steril 37:457–474Google Scholar
  11. 11.
    Wolf PH, Madans JH, Finucane FF, Higgins M, Kleinman JC (1991) Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol 164:489–494PubMedGoogle Scholar
  12. 12.
    Gibbons WF, Judd HL, Luciano AA et al (1991) Comparison sequential versus continious estrogen/progestin replacement therapy on serum lipid patterns: Multiuniversity National Upjohn study Collaborative. Society for Gynecologic InvestigationGoogle Scholar
  13. 13.
    Odmark IS, Backstrom T, Haeger M, Jonsson B, Bixo M (2004) Effects of continous combined conjugated estrogen/medroxyprogesterone acetate on lipids and lipoproteins. Maturitas 48:137–146PubMedCrossRefGoogle Scholar
  14. 14.
    Hirvonen E, Malkonen M, Mannihen V (1981) Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N Engl J Med 304:560–563PubMedCrossRefGoogle Scholar
  15. 15.
    Lobo RA, Pickar JH, Wild RA, Wash B et al (1994) Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 84:987–995PubMedGoogle Scholar
  16. 16.
    Kim CJ, Jang HC, Cho DH, Min YK (1994) Effects of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women. Arterioscler Thromb Vasc Biol 14:275–281Google Scholar
  17. 17.
    Gurakar A, Hoeg JM, Kostner G, Papadopoulos NM et al (1985) Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis 57:293–301PubMedCrossRefGoogle Scholar
  18. 18.
    Meilahn EN, Kuller LH, Matthews KA, Stein EA (1991) Lp(a) concentrations among pre-and postmenopausal women over time: the Healthy Women Study. Circulation 84(suppl II):II-546. AbstractGoogle Scholar
  19. 19.
    Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G et al (1993) Association of hormone-replacement theraby with various cardiovascular risk factors in postmenopausal women. N Engl J Med 15:1069–1075CrossRefGoogle Scholar
  20. 20.
    Wahl P, Walden CW, Knopp R, Hoover J et al (1983) Effect of estrogen progestin potency on lipid/lipoprotein cholesterol. N Engl J Med 308:862–867PubMedCrossRefGoogle Scholar
  21. 21.
    Hirvonen E, Maelkoenen M, Manninen V (1981) Effect of different progestogen on lipoproteins during postmenopausal replacement therapy. N Engl J Med 304:560–563PubMedCrossRefGoogle Scholar
  22. 22.
    Kannel WB, Hjoortland MC, McNamara PM, Gordon T (1976) Menopause and risk of cardiovascular disease. The Framingham Study. Ann Intern Med 85:447–452PubMedGoogle Scholar
  23. 23.
    Smith DC, Prentice R, Thompson DJ, Herrman WL (1975) Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 293:1164–1167PubMedCrossRefGoogle Scholar
  24. 24.
    Aygen EM, Basbug M, Tayyar M, Kaya E (1988) The effects of different doses of medroxyprogesterone acetate on serum lipids, lipoprotein levels and atherogenic index in the menopausal period. Gynecol Endocrinol 12:267–272CrossRefGoogle Scholar
  25. 25.
    Green A, Brain C (1993) Epidemiological overview of estrogen replacement and cardiovascular disease. Balliere’s Clin Endocrinol Metab 7:95–112CrossRefGoogle Scholar
  26. 26.
    Ylikorkala O, Lim P, Caubel P (2000) Effects on serum lipid profiles of continuous combined 17B-estradiol/norethisterone acetate hormone replacement therapy. Clin Ther 22:622–626PubMedCrossRefGoogle Scholar
  27. 27.
    Kojima K, Abe-Dohmae S, Arakawa R et al (2001) Progesterone inhibits apolipoprotein-mediated cellular lipid release: a putative mechanism for the decrease of high-density lipoprotein. Biochim Biophys Acta 1532:173–184PubMedGoogle Scholar
  28. 28.
    Godsland IF (2001) Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein and apolipoprotein(a) concentrations: analysis of studies published from 1974–2000. Fertil Steril 75:898–915PubMedCrossRefGoogle Scholar
  29. 29.
    van Baal WM, Kenemans P, Emeis JJ et al (1999) Long-term effects of combined hormone replacement therapy on markers of endothelial functial and inflammatory activity in healthy postmenopausal women. Fertil Steril 71:663–670PubMedCrossRefGoogle Scholar
  30. 30.
    Knopp RH (1998) The effect of postmenopausal estrogen therapy on the incidence of arteriosclerotic vascular disease. Obstet Gynecol 72:23S–30SGoogle Scholar
  31. 31.
    Baracat EC, Barbosa IC, Giordano MG et al (2002) A randomised, open-lable study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects of symptom control, bleeding pattern, lipid profile and tolerability. Climacteric 5:60–69PubMedCrossRefGoogle Scholar
  32. 32.
    Mendelsohn ME, Karas RH (1999) The protective effects of estrogen on the cardiovascular system. N Engl J med 340:1801–1811PubMedCrossRefGoogle Scholar
  33. 33.
    Erenus M, Karakoc B, Gurler A (2001) Comprasion of effects of continuous combined transdermal with oral estrogen and oral progestogen replacement therapies on serum lipoproteins and compliance. Climacteric 4:228–234PubMedCrossRefGoogle Scholar
  34. 34.
    Paterson ME, Sturdee DW, Moore B, Whitehead TP (1980) The effect of various regimens of hormone therapy on serum cholesterol and triglyceride concentrations in postmenopausal women. Br J Obstet Gynecol 87:552–560Google Scholar
  35. 35.
    Barrett-Connor E, Wingard DL, Criqui MH (1989) Postmenopausal estrogen use and heart disease risk factors in the 1980s. Rancho Bernardo, Calif, revisited. J Am Med Assoc 261:2095–2100CrossRefGoogle Scholar
  36. 36.
    Notelovitz M, Gudat JC, Ware MD, Dougherty MC (1982) Estrogen-progestin therapy and the lipid balance of postmenopausal women. Maturitas 4:301–308PubMedCrossRefGoogle Scholar
  37. 37.
    Campos H, Walsh BW, Judge H, Sacks FM (1997) Effect of estrogen on very low-density lipoprotein and low-density lipoprotein subclass metabolism in postmenopausal women. J Clin Endocrinol Metab 82:3955–3963PubMedCrossRefGoogle Scholar
  38. 38.
    Hulley SB, Rosenman RH, Bawol RD, Brand RJ (1980) Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease. N Engl J Med 302:1383–1389PubMedCrossRefGoogle Scholar
  39. 39.
    Chen FP, Lee N, Wang CC et al (1998) Effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women. Fertil Steril 69:267–273PubMedCrossRefGoogle Scholar
  40. 40.
    Walsh BW, Schiff I, Rosner B et al (1991) Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 325:1196–1204PubMedCrossRefGoogle Scholar
  41. 41.
    Assmann G, Schulte H (1992) Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 70(7):733–737PubMedCrossRefGoogle Scholar
  42. 42.
    Chen FP, Lee N, Soon YK et al (2001) Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on cargiovascular risk factors. Menopause 8:347–352PubMedCrossRefGoogle Scholar
  43. 43.
    Torng PL, Su TC, Sung FC, Chien KL, Huang SC, Chow SN et al (2000) Effects of menopause and obesity on lipid profiles in middle-aged Taiwanese women: the Chin-Shan Community Cardiovascular Cohort Study. Atherosclerosis 153:413–421PubMedCrossRefGoogle Scholar
  44. 44.
    Farish E, Fletcher CD, Hart DM, Dagen MM, Parkin DE (1986) Lipoprotein and apoprotein levels in postmenopausal women during treatment with norethisterone. Clin Chim Acta 159:147–151PubMedCrossRefGoogle Scholar
  45. 45.
    Melchior GW, Castle CK, Vidmar TJ, Politers HG et al (1990) Apo A-I metabolism in cynomolgus monkeys: male-female differences. Biochem Biophys Acta 1043:97–105PubMedGoogle Scholar
  46. 46.
    Schaefer EJ, Foster DM, Zech LA, Lindgren FT et al (1983) The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J Clin Endocrinol Metab 57:262–267PubMedCrossRefGoogle Scholar
  47. 47.
    Castelo-Branco C, Vicente JJ, Figueras F et al (1999) Two years prospective and comparative study on the effects of tibolone on lipid pattern, behavior of apolipoproteins AI and B. Menopause 6:22–27CrossRefGoogle Scholar
  48. 48.
    Tonstad S (1996) Combined hormone replacement therapy vith estradiol and norethisterone acetate: effects in hyperlipidemia. Br J Obstet Gynecol 103(suppl 13):45–48Google Scholar
  49. 49.
    Soma M, Fumagalli R, Paoletti R et al (1991) Plasma Lp(a) concentration after estrogen and progestagen in postmenopausal women. Lancet 1:612CrossRefGoogle Scholar
  50. 50.
    Brown SA, Hutchinson R, Morriseft J, Boerwinkle E, Davis CE, Gotto AM (1993) Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communites: The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 13:1139–1158Google Scholar
  51. 51.
    Marcovina SM, Alber JJ, Jacobs DR Jr et al (1993) Lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in Caucasians and African Americans: The CARDIA Study. Arterioscler Thromb Vasc Biol 13:1037–1045Google Scholar
  52. 52.
    Jenner JL, Ordovas JM, Lamon-Fava S, Schaefer MM, Wilson PWF et al (1993) Effect of age, sex, and menopausal status on plasma lipoprotein(a) levels: the Framingham Offspring Study. Circulation 87:1135–1141PubMedGoogle Scholar
  53. 53.
    Smolders RG, Vogelvang TE, Mijatovic V et al (2002) A 2-year randomized, comparative study on the effects of reloxifene on lipoprotein(a) and homocysteine. Maturitas 4:105–114CrossRefGoogle Scholar
  54. 54.
    Bostom AG, Cupples LA, Jenner JL et al (1996) Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. J Am Med Assoc 276:544–548CrossRefGoogle Scholar
  55. 55.
    Kim CJ, Min YK, Ryu WS et al (1996) Effects of hormon replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of theray. Arch Intern Med 156:1693–1700PubMedCrossRefGoogle Scholar
  56. 56.
    Schaefer EJ, Lamon-Fava S, Jenner JL et al (1994) Lipoprotein(a) levels and the risk of coronary heart disease in men: The Lipid research Clinics Coronary Primary Prevention Trial. JAMA 271:999–1003PubMedCrossRefGoogle Scholar
  57. 57.
    Walsh BW, Kuller LH, Wild RA et al (1998) Effects of raloxifene on serum lipids and coagulation factors in health postmenopausal women. J Am Med Assoc 279:1445–1451CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  1. 1.Biochemistry Dept., Faculty of MedicineHacettepe UniversityAnkaraTurkey
  2. 2.Biochemistry Dept., Faculty of MedicineBaşkent UniversityAnkaraTurkey
  3. 3.Obstetrics and Gynecology Dept., Faculty of MedicineKocaeli UniversityKocaeliTurkey
  4. 4.Obstetrics and Gynecology Dept., Faculty of MedicineHacettepe UniversityAnkaraTurkey
  5. 5.AnkaraTurkey

Personalised recommendations